CN105833184A - Traditional Chinese medicine composition, fermented medicine liquor prepared from traditional Chinese medicine composition, preparation method and application - Google Patents

Traditional Chinese medicine composition, fermented medicine liquor prepared from traditional Chinese medicine composition, preparation method and application Download PDF

Info

Publication number
CN105833184A
CN105833184A CN201610302578.1A CN201610302578A CN105833184A CN 105833184 A CN105833184 A CN 105833184A CN 201610302578 A CN201610302578 A CN 201610302578A CN 105833184 A CN105833184 A CN 105833184A
Authority
CN
China
Prior art keywords
parts
chinese medicine
medicine composition
rhizoma
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201610302578.1A
Other languages
Chinese (zh)
Other versions
CN105833184B (en
Inventor
梅志刚
谭凌菁
黄卫锋
张文丽
张世忠
李小丽
王金凤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Yishenrui Technology Co ltd
Guangxi Chuse Biotechnology Co ltd
Original Assignee
China Three Gorges University CTGU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Three Gorges University CTGU filed Critical China Three Gorges University CTGU
Priority to CN201610302578.1A priority Critical patent/CN105833184B/en
Publication of CN105833184A publication Critical patent/CN105833184A/en
Application granted granted Critical
Publication of CN105833184B publication Critical patent/CN105833184B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/287—Chrysanthemum, e.g. daisy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/89—Cyperaceae (Sedge family)
    • A61K36/8905—Cyperus (flatsedge)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A61K36/8988—Gastrodia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction

Abstract

The invention discloses a traditional Chinese medicine composition, fermented medicine liquor prepared from the traditional Chinese medicine composition, a preparation method and application. The traditional Chinese medicine composition is prepared from, by weight, 160-480 parts of kudzuvine roots, 80-320 parts of radix salvia miltiorrhiza, 120-400 parts of radix paeoniae alba, 120-400 parts of milkvetch roots, 40-240 parts of rhizoma curcumae longae, 60-280 parts of rhizoma atractylodis macrocephalae, 40-240 parts of semen brassicae, 60-280 parts of fructus crataegi, 60-280 parts of radix bupleuri, 60-280 parts of flos chrysanthemi, 40-240 parts of rhizoma gastrodiae, 60-280 parts of rhizome panacis japonica, 60-280 parts of rhizoma cyperi and 40-240 parts of herba salviae chinensis. Every 1,000 parts by weight of the fermented medicine liquor is prepared by adding and fermenting, by weight, 10-50 parts of saccharomyces cerevisiae, 10-50 parts of bacillus aceticus, 10-50 parts of lactobacillus and the balance traditional Chinese medicine decoction. Experiments show that the fermented medicine liquor has the obvious effect on oxidative stress injuries of cerebral microvascular endothelial cells and can significantly inhibit cerebral microvascular endothelial cell apoptosis and aging which are induced by hydrogen peroxide. Clinical experiments show that the fermented medicine liquor prepared from the traditional Chinese medicine composition can effectively treat ischemic encephalopathy, is safe and effective in treatment, has no adverse influence on the liver and kidney functions of a patient, can be taken for a long term and is worthy of clinical application and popularization.

Description

A kind of Chinese medicine composition, its fermentation medicinal liquid prepared and preparation method and application
Technical field
The present invention relates to technical field of Chinese medicines, a kind of Chinese medicine composition, its fermentation medicinal liquid prepared and preparation method and application, it is particularly suitable for the treatment of ischemic encephalopathy.
Background technology
Ischemic encephalopathy (ischemic encephalopathy): refer to due to hypotension, sudden cardiac arrest, lose blood, brain injury that the reason such as suffocate causes.The encephalopathy caused after cerebral ischemia in clinic includes cerebral infarction, vascular dementia, headache, dizziness, depression, tinnitus and insomnia etc., has high incidence, high disability rate, the feature of high mortality.It is one of three big principal diseases causing human death, is only second to heart disease and cancer.
The main cause causing ischemic encephalopathy has: the 1. inside and outside stricture of artery of cranium or obturation；2. cerebral embolism；3. vascular lesion；4. Hemodynamic Factors；5. hematologic agent etc..In ischemic encephalopathy evolution, produce a series of cascade reaction include the disorder of energy decline, calcium balance, response to oxidative stress, the activation of phospholipase, arachidonic release etc..Research to Mechanism of Cerebral Ischemic Injury at present is concentrated mainly on the aspects such as oxygen-derived free radicals, excitatory amino acid, intracellular calcium overload, mitochondrial damage, inflammatory reaction and apoptosis.
Modern surgical treatment Ischemic Encephalopathy mainly utilizes the time (treatment window) of the neuron tolerance ischemia of Penumbra zone, uses various method to recover cerebral blood flow, saves dying neurocyte, and expectant treatment is then based on thrombolytic.Although have developed some medicines in the market, having multiformity and complexity yet with ischemic encephalopathy, though these medicines have manifested certain curative effect in the treatment, but being all by single mechanisms play effect, some is not enough in total existence.
Summary of the invention
It is an object of the invention to provide a kind of Chinese medicine composition, its fermentation medicinal liquid prepared and preparation method and application, overcoming prior art not enough, it is evident in efficacy, safe and reliable and economical and practical, can effectively reduce the M & M of ischemic encephalopathy, improve the quality of living.
For solving above-mentioned technical problem, the technical solution adopted in the present invention is: a kind of Chinese medicine composition, following raw material including by weight: Radix Puerariae 160-480 part, Radix Salviae Miltiorrhizae 80-320 part, Radix Paeoniae Alba 120-400 part, Radix Astragali 120-400 part, Rhizoma Curcumae Longae 40-240 part, Rhizoma Atractylodis Macrocephalae 60-280 part, Semen Sinapis Albae 40-240 part, Fructus Crataegi 60-280 part, Radix Bupleuri 60-280 part, Flos Chrysanthemi 60-280 part, Rhizoma Gastrodiae 40-240 part, Rhizoma Panacis Japonici 60-280 part, Rhizoma Cyperi 60-280 part, Herba Salviae Chinensis 40-240 part.
Preferably in scheme, combining clinical syndrome differentiation according to giving consideration to both the incidental and fundamental principle and treat observation of curative effect, the raw material of this Chinese medicine composition is: Radix Puerariae 320 parts, Radix Salviae Miltiorrhizae 160 parts, the Radix Paeoniae Alba 240 parts, the Radix Astragali 240 parts, 80 parts of Rhizoma Curcumae Longae, the Rhizoma Atractylodis Macrocephalae 120 parts, Semen Sinapis Albae 80 parts, Fructus Crataegi 120 parts, Radix Bupleuri 120 parts, Flos Chrysanthemi 120 parts, 80 parts of Rhizoma Gastrodiae, Rhizoma Panacis Japonici 120 parts, Rhizoma Cyperi 120 parts, Herba Salviae Chinensis 80 parts.
The invention still further relates to the preparation method of described Chinese medicine composition, will weigh raw material of Chinese medicine by proportioning, add the water of raw material gross weight 8-10 times, elder generation's intense fire is heated to seething with excitement slow fire boiling 30-60min again, decoct to the 4-5 times of water yield, remove slag and be filtrated to get the decocting for Chinese herbal medicine liquid of this Chinese medicine composition.
Further, the raw material of Chinese medicine after adding water first soaks 20-60min, then carries out heating and decocts.
The invention still further relates to the fermentation medicinal liquid of a kind of Chinese medicine composition, by weight: containing yeast 10-50 part, acetobacter 10-50 part, lactobacillus 10-50 part, remaining the decocting for Chinese herbal medicine liquid prepared for Chinese medicine composition in every 10000 parts of fermentation medicinal liquids.
Preferably in scheme, combine clinical syndrome differentiation according to giving consideration to both the incidental and fundamental principle and treat observation of curative effect, the fermentation medicinal liquid of this Chinese medicine composition, by weight: containing 10 parts of yeast, acetobacter 10 parts, lactobacillus 10 parts, remaining the decocting for Chinese herbal medicine liquid prepared for Chinese medicine composition in every 10000 parts of fermentation medicinal liquids.
The method that the invention still further relates to described fermentation medicinal liquid, concretely comprises the following steps, and after taking yeast, acetobacter and lactobacillus by proportioning, adds decocting for Chinese herbal medicine liquid, 22-37 DEG C of bottom fermentation 10-20 days, filters, and sterilization i.e. can obtain the medicinal liquid finished product that ferments.
The invention still further relates to the medicinal liquid application in terms of preparation treatment ischemic encephalopathy medicine of fermenting of described Chinese medicine composition or Chinese medicine composition.
The invention still further relates to the medicinal liquid application in terms of apoptosis of vascular endothelial cell medicine caused by preparation treatment oxidative stress of fermenting of described Chinese medicine composition or Chinese medicine composition
The invention still further relates to the application in terms of the medicines such as medicinal liquid preparation treatment vascular dementia, headache, dizziness, tinnitus that ferment of described Chinese medicine composition or Chinese medicine composition.
Further, the invention still further relates to the medicinal liquid application in terms of the Injury of Cerebral Microvascular Endothelial Cells medicine that preparation treatment oxidative stress causes of fermenting of described Chinese medicine composition or Chinese medicine composition.
Further, the present invention also can play a role in terms of the clinical ischemic cerebrovascular for the treatment of.
The herbal pharmacology mechanism of the present invention:
Radix Puerariae: sweet, pungent, cool.Return spleen, stomach warp.Expelling pathogenic factors from muscles for reducing heat, rash, promoting the production of body fluid to quench thirst, yang invigorating antidiarrheal.Cure mainly fever caused by exogenous pathogens headache, hypertension neck pain, thirsty, quench one's thirst, measles without adequate eruption, hematodiarrhoea, have loose bowels.Its main component Radix Puerariae total flavones and puerarin can reduce platelet aggregation, expand blood vessel, improve microcirculation, reduce vascular resistance, make blood flow increase, and then improve cerebral ischemic condition, prevent and treat the cerebrovascular disease such as cerebral infarction, hemiplegia.
Radix Salviae Miltiorrhizae: bitter, is slightly cold.Enter the heart, Liver Channel.Blood circulation promoting and blood stasis dispelling, inducing menstruation to relieve menalgia, clear away heart-fire relieving restlessness, removing heat from blood eliminating carbuncle.Cure mainly head, the breast side of body, abdomen pain due to blood stasis, accumulation, menoxenia, dysmenorrhea amenorrhea, puerperal the stagnant stomachache of the stasis of blood, arthralgia, traumatic injury congestive edema, epidemic febrile disease is vexed, palpitation due to deficiency of blood, sore swollen toxin, red rash scabies.Radix Salviae Miltiorrhizae can antithrombus formation, suppress platelet aggregation, expand peripheral blood vessel simultaneously, increase cerebral blood flow, improve microcirculation.
The Radix Paeoniae Alba: cool, bitter in the mouth acid, it is slightly cold.Enter liver, spleen channel.Enrich blood easing the affected liver, suppressing the hyperactive liver pain relieving.Curing mainly the chest and abdomen pain over the hypochondriac region, dysentery is suffered from abdominal pain, spontaneous sweating, fever due to yin deficiency.Its main component peoniflorin can antithrombotic and platelet aggregation, simultaneously can spasmolytic, analgesia, human body cardiovascular and cerebrovascular vessel are had and well protect and take good care of effect.
The Radix Astragali: sweet, tepor.Return lung, spleen, liver, kidney channel.Benefiting QI for strengthening the superficies, arresting sweating are admittedly de-, torr skin ulcer granulation promoting, inducing diuresis to remove edema.Curing mainly the deficiency of vital energy weak, sinking of QI of middle-JIAO, chronic diarrhea proctoptosis, metrorrhagia of having blood in stool, exterior deficiency spontaneous perspiration, carbuncle difficulty is burst, and bursts for a long time and does not holds back, blood deficiency and yellow complexion, and interior-heat is quenched one's thirst, chronic nephritis, albuminuria, diabetes.The Radix Astragali has antioxidation, and its main component Radix Astragali total flavones can increase SOD activity, reduces lipid peroxide to biomembranous damage.Additionally, the expansible peripheral blood vessel of the Radix Astragali, reduce Peripheral resistance, protect cerebrovascular.
Rhizoma Curcumae Longae: pungent, bitter, temperature.Return spleen, Liver Channel.Removing blood stasis circulation of qi promoting, inducing menstruation to relieve menalgia.Cure mainly the breast side of body to twinge, amenorrhea, abdominal mass, rheumatism shoulder arm pain, tumbling and swelling.Curcumin has antioxidation, analgesic activity, may also suppress platelet aggregation, reduces blood viscosity, antithrombus formation.
The Rhizoma Atractylodis Macrocephalae: bitter, sweet, temperature.Return spleen, stomach warp.Invigorating the spleen and benefiting QI, dampness diuretic, hidroschesis, antiabortive.Cure mainly insufficiency of the spleen lack of appetite, abdominal distention is had loose bowels, phlegm retention vertigo and palpitation, edema, spontaneous perspiration, frequent fetal movement.The Rhizoma Atractylodis Macrocephalae can substantially suppress platelet aggregation, expands blood vessel.
Semen Sinapis Albae: pungent, warm.Attach to the lung and stomach meridians.Warming the lung eliminating phlegm promoting the circulation of QI, resolving mass and removing the obstruction of the collateral pain relieving.Cure mainly cough with asthma abundant expectoration；Fullness in the chest and hypochondriac pain；Numb limbs and tense tendons；Arthralgia；Multiple abscess caused by damp-phlegm；Carbuncle of yin nature toxic swelling.Controlling acute mastitis, breast carcinoma, mammary gland pain, tuberculosis, phlegm retention cough with asthma, fullness and distention in the chest and hypochondrium pain, regurgitation is vomitted, aphasia due to apoplexy, and limbs arthralgia pain is numb, tinea pedis, carbuncle of yin nature, toxic swelling, treating swelling and pain by traumatic injury.Can treat by wind-induced numb limbs and tense tendons, the sequela such as dysphasia.
Fructus Crataegi: tepor, sour in the mouth is sweet.Return spleen, stomach, Liver Channel.Promoting digestion and invigorating the stomach, activating blood circulation to dissipate blood stasis, convergence dysentery relieving.Cure mainly carnivorous stagnant long-pending, lump in the abdomen, abdominal distention feeling of fullness, stasis blocking stomachache, phlegm retention, have loose bowels, discharging fresh blood stool etc..Fructus Crataegi can contact local congestion state, reduces blood pressure and cholesterol, vessel softening, and flavonoid and vitamin C, carotene contained by Fructus Crataegi can block and reduce free radical and generate simultaneously, antioxidation and defying age.
Radix Bupleuri: be slightly cold, bitter in the mouth, pungent.Return Liver Channel, gallbladder meridian.Expelling pathogenic factors from the exterior expels the heat-evil, dispersing the stagnated live-QI to relieve the stagnation of QI.Cure mainly cold, fever, alternate attack of chill and fever, malaria, stagnation of QI due to depression of the liver, sternal rib pain, proctoptosis, uterus come off, menoxenia.Saikoside scalable nerve centre, regulates relieving mood, and has antiinflammatory, enhancing immunity effect.
Flos Chrysanthemi: sweet, be slightly cold.Return lung, Liver Channel.Dispelling wind and heat pathogens, suppressing the hyperactive liver improving eyesight, disappear and cough pain relieving.Cure mainly the disease effects such as headache dizziness, conjunctival congestion and swelling pain, anemopyretic cold, cough notable, also there is effect of refreshment.Flos Chrysanthemi can reduce glutathion peroxidating, the damage of biomembranous ultra-oxygen anion free radical is had obvious protective function, can also affect the permeability of mice blood capillary simultaneously, increase capillary resistance, thus have antiinflammatory action.
Rhizoma Gastrodiae: sweet, flat.Return Liver Channel.Endogenous wind stopping relieving convulsion, suppressing liver-YANG, dispelling wind and removing obstruction in the collateral.Gastrodine can treat cerebrovascular headache, and increases periphery and coronary artery blood flow, protects cardiovascular and cerebrovascular vessel.Additionally, the sequela such as wind-induced facial nerve tics, numb limbs and tense tendons, hemiplegia, hypomnesis also has improvement result in for.
Rhizoma Cyperi: micro-hardship is sweet, flat.Enter liver, tri-jiao channel.Regulate the flow of vital energy resolving depression, menstruction regulating and pain relieving.Cure mainly breast, the side of body, abdominal distention, dyspepsia, menoxenia, amenorrhea dysmenorrhea, colic of cold type stomachache, distending pain of the breast.The aqueous solution of Rhizoma Cyperi total alkaloids, glycoside, flavonoid and phenolic compound has obvious hypotensive effect and antiinflammatory action, it is possible to decrease inflammatory reaction when peripheral blood resistance and cerebral ischemia re-pouring.
Rhizoma Panacis Japonici: hardship sweet, micro-, temperature.Enter liver, tri-jiao channel.Dispelling wind and heat pathogens, suppressing the hyperactive liver improving eyesight.Cure mainly the most weak；Inappetence；Cough due to consumptive disease；Spitting of blood；Spit blood；Epistaxis；Have blood in stool hematuria；Vicarious menstruation；Metrorrhagia；Traumatic hemorrhage；Lump in the abdomen；Blood stasis amenorrhea；Puerperal, stasis of blood the moon was suffered from abdominal pain；Traumatic injury；Rheumatic arthritis；Carbuncle；Hemorrhoid；Venom.Panax japonicus total Saponin has stronger removing superoxide anion radical effect and antiinflammatory action, can protect cardiovascular and cerebrovascular vessel, antitumor and defying age.
Herba Salviae Chinensis: have another name called Salvia chinensis, cold, bitter in the mouth.Enter liver, gallbladder meridian.Blood circulation promoting and blood stasis dispelling, clearing away heat-damp and promoting diuresis, mass dissipating and swelling eliminating.Main menoxenia；Dysmenorrhea；Amenorrhea；Metrorrhagia, has blood in stool；Jaundice due to damp-heat；Hot toxic-heat and blood stasis；Drench pain；Leukorrhagia；Rheumatic ostalgia；Scrofula；Skin ulcer swells；Acute mastitis；Herpes zoster；Leprosy；Traumatic injury wound is swollen.Its extract salvianolic acid B can alleviate the inflammatory reaction of rats after cerebral ischemic reperfusion and the apoptosis of ischemic tissue of brain.
Beneficial effects of the present invention:
Chinese medicine thinks that the basic pathogenesis of ischemic encephalopathy is imbalance of YIN and YANG, and QI and blood is inverse disorderly, and with the hepatic and renal YIN deficiency, QI and blood declines few for void；With wind, fire, expectorant, gas, the stasis of blood as reality, therefore the present invention uses suppressing the hyperactive liver to relieve the wind syndrome, waking up the patient from unconsciousness by dissipating phlegm, removing heat by catharsis expells the pathogenic heat, nourishing the liver and kidney, benefiting QI and nourishing blood method for the treatment of cube.Wherein Radix Puerariae induces sweat removing heat from blood of bringing down a fever, and yang invigorating can enter nicergoline network, and Radix Astragali QI invigorating is with handsome blood, and Semen Sinapis Albae is eliminated phlegm for resuscitation, Radix Paeoniae Alba YIN nourishing pain relieving, Fructus Crataegi promoting blood circulation to restore menstrual flow blood stasis dispelling, Rhizoma Atractylodis Macrocephalae invigorating the spleen and benefiting QI, Rhizoma Gastrodiae suppressing the hyperactive liver to relieve the wind syndrome qi-restoratives, Radix Bupleuri expelling pathogenic factors from the exterior expels the heat-evil, dispersing the stagnated live-QI to relieve the stagnation of QI, rises and lifts yang-energy, Flos Chrysanthemi dispelling wind and heat pathogens, suppressing the hyperactive liver improving eyesight, Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling, inducing menstruation to relieve menalgia, Herba Salviae Chinensis regulating menstruation and activating blood, Rhizoma Cyperi regulates the flow of vital energy resolving depression, inducing menstruation to relieve menalgia, Rhizoma Panacis Japonici strengthening by means of tonics, eliminating stasis to stop pain, hemostasis is eliminated the phlegm.Making a general survey of full side, all medicines share, it is possible to suppressing the hyperactive liver to relieve the wind syndrome, eliminating thrombus and removing obstruction in channels, inhibition thrombosis, the effect of preventing and treating ischemic encephalopathy.Compared with the Chinese medicine composition of existing open invention and fermentation medicinal liquid, the raw material of Chinese medicine of the present invention is simple and easy to get, and fermentation medicinal liquid preparation method is simple, quickly, has the advantages such as scientific formula, dialectical prescribe medicine, mechanism is distinct, safe and efficient.And verify through experiment and clinical observation, this fermentation medicinal liquid has suppressing the hyperactive liver to relieve the wind syndrome, eliminating thrombus and removing obstruction in channels, inhibition thrombosis, protection cerebrovascular, the effect of preventing and treating ischemic encephalopathy.
Accompanying drawing explanation
Accompanying drawing 1 is variable concentrations H2O2Impact on BMECs proliferation activity, vertical coordinate is ability of cell proliferation, represents with %.
Accompanying drawing 2 is the impact on BMECs proliferation activity of the fermentation medicinal liquid (hereinafter referred to as STL) of Chinese medicine composition, and vertical coordinate is ability of cell proliferation, represents with %.
Accompanying drawing 3 is that the present invention is to H2O2The impact of the BMECs proliferation activity of induction, vertical coordinate is ability of cell proliferation, represents with %.
Accompanying drawing 4 is that the present invention is to H2O2The impact of the BMECs apoptosis situation of induction；Wherein A: normal group, B:H2O2(400 μm ol/L) group, C:H2O2(400 μm ol/L)+STL (0.025g/L) group, D:H2O2(400 μm ol/L)+STL (0.05g/L) group, E:H2O2(400 μm ol/L)+STL (0.1g/L) group.
Accompanying drawing 5 is that the present invention is to H2O2The impact of the old and feeble situation of the BMECs of induction；Wherein A: normal group, B:H2O2(400 μm ol/L) group, C:H2O2(400 μm ol/L)+STL (0.025g/L) group, D:H2O2(400 μm ol/L)+STL (0.05g/L) group, E:H2O2(400 μm ol/L)+STL (0.1g/L) group.
Accompanying drawing 6 is that the present invention is to H2O2The ROS activity influence of the BMECs of induction.Wherein A: normal group, B:H2O2(400 μm ol/L) group, C:STL (0.1g/L) group, D:H2O2(400 μm ol/L)+STL (0.1g/L) group, E:H2O2(400 μm ol/L)+STL (0.1g/L)+inhibitor group.
Accompanying drawing 7-8 is that the present invention is to H2O2The SOD activity influence of the BMECs of induction, the vertical coordinate in Fig. 7 is average fluorescent strength.
Accompanying drawing 9 is that the present invention is to H2O2The GSH level impact of the BMECs of induction.
Accompanying drawing 10-11 is that the present invention is to H2O2The impact of the sirt1 protein expression level of the BMECs of induction；In Figure 10 1: normal group, 2:H2O2(400 μm ol/L) group, 3:STL (0.1g/L) group, 4:H2O2(400 μm ol/L)+STL (0.1g/L) group, 5:STL (0.1g/L)+inhibitor group, 6:H2O2(400 μm ol/L)+STL (0.1g/L)+inhibitor group.
Accompanying drawing 12-13 is that the present invention is to H2O2The impact of the p21 protein expression level of the BMECs of induction, Tu12Zhong, 1: normal group, 2:H2O2(400 μm ol/L) group, 3:STL (0.1g/L) group, 4:H2O2(400 μm ol/L)+STL (0.1g/L) group, 5:STL (0.1g/L)+inhibitor group, 6:H2O2(400 μm ol/L)+STL (0.1g/L)+inhibitor group.
Accompanying drawing 14-15 is that the present invention is to H2O2The impact of the PGC-1 α protein expression level of the BMECs of induction；In Figure 14 1: normal group, 2:H2O2(400 μm ol/L) group, 3:STL (0.1g/L) group, 4:H2O2(400 μm ol/L)+STL (0.1g/L) group, 5:STL (0.1g/L)+inhibitor group, 6:H2O2(400 μm ol/L)+STL (0.1g/L)+inhibitor group.
Detailed description of the invention
Below in conjunction with being embodied as and form, it is further elucidated with the present invention.These embodiments are interpreted as being merely to illustrate the present invention rather than for limiting the scope of the invention.After having read the content that the present invention records, the present invention can be made various changes or modifications by those skilled in the art, and these equivalence changes and modification fall into claims of the present invention limited range equally.
Embodiment 1: a kind of Chinese medicine composition fermentation medicinal liquid and preparation method thereof, every 10000 parts of fermentation medicinal liquids, by 10 parts of yeast, acetobacter 10 parts, lactobacillus 10 parts, add decocting for Chinese herbal medicine liquid, and ferment 15 days in 22 DEG C, filtering, pasteurization packaging is canned obtains the medicinal liquid finished product that ferments.Decocting for Chinese herbal medicine liquid is that following raw material is made: Radix Puerariae 160 parts, Radix Salviae Miltiorrhizae 80 parts, the Radix Paeoniae Alba 120 parts, the Radix Astragali 120 parts, 40 parts of Rhizoma Curcumae Longae, the Rhizoma Atractylodis Macrocephalae 60 parts, Semen Sinapis Albae 40 parts, Fructus Crataegi 60 parts, Radix Bupleuri 60 parts, Flos Chrysanthemi 60 parts, 40 parts of Rhizoma Gastrodiae, Rhizoma Panacis Japonici 60 parts, Rhizoma Cyperi 60 parts, Herba Salviae Chinensis 40 parts.The preparation method of decoction liquor is: by various Chinese medicines and water by weight for 1:10, soak Chinese medicine 20 minutes, and intense fire is heated to seething with excitement slow fire boiling again 60 minutes, decocts to 5 times of water yields, removes slag and be filtrated to get decocting for Chinese herbal medicine liquid.
Embodiment 2: a kind of Chinese medicine composition fermentation medicinal liquid and preparation method thereof, every 10000 parts of fermentation medicinal liquids, by 40 parts of yeast, acetobacter 40 parts, lactobacillus 40 parts, add decocting for Chinese herbal medicine liquid, and ferment 10 days in 30 DEG C, filtering, pasteurization packaging is canned obtains the medicinal liquid finished product that ferments.Decocting for Chinese herbal medicine liquid is that following raw material is made: Radix Puerariae 160 parts, Radix Salviae Miltiorrhizae 320 parts, the Radix Paeoniae Alba 240 parts, the Radix Astragali 120 parts, 80 parts of Rhizoma Curcumae Longae, the Rhizoma Atractylodis Macrocephalae 240 parts, Semen Sinapis Albae 80 parts, Fructus Crataegi 120 parts, Radix Bupleuri 120 parts, Flos Chrysanthemi 120 parts, 80 parts of Rhizoma Gastrodiae, Rhizoma Panacis Japonici 120 parts, Rhizoma Cyperi 80 parts, Herba Salviae Chinensis 120 parts.The preparation method of decoction liquor is: by various Chinese medicines and water by weight for 1:8, soak Chinese medicine 40 minutes, and intense fire is heated to seething with excitement slow fire boiling again 50 minutes, decocts to 5 times of water yields, removes slag and be filtrated to get decocting for Chinese herbal medicine liquid.
Embodiment 3: a kind of Chinese medicine composition fermentation medicinal liquid and preparation method thereof, every 10000 parts of fermentation medicinal liquids, by 50 parts of yeast, acetobacter 50 parts, lactobacillus 50 parts, add decocting for Chinese herbal medicine liquid, and ferment 20 days in 37 DEG C, filtering, pasteurization packaging is canned obtains the medicinal liquid finished product that ferments.Decocting for Chinese herbal medicine liquid, it is that following raw material is made: Radix Puerariae 480 parts, Radix Salviae Miltiorrhizae 320 parts, the Radix Paeoniae Alba 400 parts, the Radix Astragali 400 parts, 240 parts of Rhizoma Curcumae Longae, the Rhizoma Atractylodis Macrocephalae 280 parts, Semen Sinapis Albae 240 parts, Fructus Crataegi 280 parts, Radix Bupleuri 280 parts, Flos Chrysanthemi 280 parts, 240 parts of Rhizoma Gastrodiae, Rhizoma Panacis Japonici 280 parts, Rhizoma Cyperi 280 parts, Herba Salviae Chinensis 240 parts.The preparation method of decoction liquor is: by various Chinese medicines and water by weight for 1:9, soak Chinese medicine 60 minutes, and intense fire is heated to seething with excitement slow fire boiling again 30 minutes, decocts to 4 times of water yields, removes slag and be filtrated to get decocting for Chinese herbal medicine liquid.
Above-mentioned herb fermenting medicinal liquid each takes 60mL, and morning, noon and afternoon every day respectively take 1 time.The suitable one after each meal of the bad person of gastrointestinal system.
The diagnostic criteria of cerebral infarction: 1. primary symptom: hemiplegia, god know unconsciousness, speech not smoothgoing puckery or in silence, hemiparesthesia, crooked mouth and tongue；The most secondary disease: headache, dizziness, pupil god change, drinking-water send out choke, mesh the most not wink, ataxia；3. Acute onset, premorbid has inducement more, often has premonitory symptom；4. age of onset is many more than 40 years old.
Possess more than two primary symptoms, or two diseases of a primary symptom, can make a definite diagnosis in conjunction with onset, inducement, premonitory symptom, age；Do not possess above-mentioned condition, also can make a definite diagnosis in conjunction with imaging examination result.
Curative effect determinate standard: substantially recover: >=81%, less than 6 points；Marked improvement: 56%～80%；Progressive: 36%～55%；The most progressive: 11%～35%；Unchanged: ＜ 11%；Deteriorate: (including death) negative value.
In order to the substantive distinguishing features of the present invention, effectiveness and safety are better described, using below and intend ischemic injuries brain microvessel endothelial cells in vitro oxidativestress damage model, the Chinese medicine preparation of the application present invention processes, and observes therapeutic effect and potential mechanism.
Recording to map and statistical result is convenient, following Chinese medicine composition fermentation medicinal liquid STL represents.
Experimental technique
1) cell cultivate: purchased from Shanghai this letter bio tech ltd Brain Microvascular Endothelial (BMEC) with containing 10% hyclone, the DMEM high glucose medium of 1% mycillin, in 37 DEG C, containing 5%CO2Incubator in cultivate, within every 2 days, change liquid once, take growth conditions and stablize and be in the cell of logarithmic (log) phase for testing.
2) cell model is set up: the BMEC cell of trophophase of taking the logarithm is inoculated in 96 orifice plates, after cell attachment, inhales and abandons liquid in hole, adds the H of variable concentrations (50-800 μm ol/L) by every hole 100 μ L2O2, blank normal group only adds culture medium, and each concentration sets 6 multiple holes.Hydrogen peroxide adds 20 μ l MTT (5mg/mL) after stimulating 24h to be continued to hatch 4h, abandons supernatant, and every hole adds 150 μ L DMSO and dissolves, and measures the light absorption value OD in each hole at enzyme-linked immunosorbent assay instrument 570nm570nm, determine 503nhibiting concentration (IC50)。
3) experiment packet: (1) normal group；(2)H2O2(400 μm ol/L) processes 24h group；(3) variable concentrations STL (1.25g/L-40g/L) processes 12h group；(4) after variable concentrations STL (0.0125g/L-0.4g/L) pretreatment 12h, abandoning supernatant, add H2O2(400 μm ol/L) processes 24h group.The light absorption value OD in each hole of measurement at 570nm is measured at enzyme-linked immunosorbent assay instrument with mtt assay570nm。
4) experimentation:
1. DAPI dyeing: the BMEC cell of trophophase of taking the logarithm is inoculated in 6 orifice plates, and 6 well culture plates are placed in 37 DEG C, containing 5%CO by every hole 1000 μ L2Incubator in cultivate.After cultivating 20h, if Normal group, H2O2(400 μm ol/L) group, variable concentrations STL (0.025g/L, 0.05g/L, 0.1g/L)+H2O2(400 μm ol/L) group.Abandon supernatant after STL pretreatment 12h, add H2O2Continue to cultivate 24h.Old culture fluid is abandoned in suction, and PBS rinses 5 minutes；The paraformaldehyde room temperature of 4% is fixed 15 minutes PBS and is rinsed 3 times, each 10 minutes；DAPI working solution room temperature dyes 20 minutes；PBS rinsing 3 times, each 10 minutes；Fluorescence microscope is also taken pictures.
2. beta galactosidase dyeing: the BMEC cell of trophophase of taking the logarithm is inoculated in 6 orifice plates, every hole 1000 μ L by 6 well culture plates in 37 DEG C, containing 5%CO2Incubator in cultivate.After cultivating 20h, if normal group, H2O2(400 μm ol/L) group, variable concentrations STL (0.025g/L, 0.05g/L, 0.1g/L) group+H2O2(400 μm ol/L) group.Abandon supernatant after STL pretreatment 12h, add H2O2Continue to cultivate 24h.Old culture fluid is abandoned in suction, and every hole adds the PBS of 2mL and washs 3 times；Every hole adds 1mL beta galactosidase dyeing fixative, and room temperature fixes 15min, sucking-off dyeing fixative, every hole adds 2mLPBS and washs three times, each 3min, sucking-off PBS, every hole adds 1mL working solution, 37 ° of overnight incubation, seals six orifice plates with preservative film and prevents evaporation.Observe under ordinary optical microscope and take pictures.
3. DCFH-DA probe load: the BMECs of trophophase of taking the logarithm is inoculated in 6 orifice plates, every hole 1000 μ L by 6 well culture plates in 37 DEG C, containing 5%CO2Incubator in cultivate.After cultivating 20h, if normal group, H2O2(400 μm ol/L) group, STL (0.1g/L) group, STL (0.1g/L)+H2O2(400 μm ol/L) group.Abandon supernatant after STL pretreatment 12h, add H2O2Continue to cultivate 24h.Hydrogen peroxide stimulates 12h, processes cell, fluorescence microscopy Microscopic observation according to ROS detection kit, takes pictures, calculate average optical with IPP6.0.
4. SOD Activity determination: the cell of trophophase of taking the logarithm is inoculated in 6 orifice plates, every hole adds 2mL, within 12 hours in advance, adds Chinese medicine, after hatching end, abandons supernatant, add H2O2Processing 24 hours, cell is divided into normal group, H2O2(400 μm ol/mL) group, STL (0.1g/L) group, STL (0.1g/L)+H2O2(400 μm ol/mL) group, sirt1 inhibitor group, Chinese medicine adds hydrogen peroxide inhibiting group.After acting on 36 hours, by cell with after 4 DEG C of PBS 2 times, scrape in the centrifuge tube that cell puts into 1.5mL with cell scraper after adding lysate, on ice cracking 30 minutes, used vortex oscillator to shake 30 seconds every 5 minutes.4 DEG C of 1000rpm are centrifuged 10 minutes, collect supernatant.Operate according to SOD test kit reagent preparation, detect by microplate reader.
5. GSH Activity determination: the cell of trophophase of taking the logarithm is inoculated in 6 orifice plates, every hole adds 2mL, within 12 hours in advance, adds Chinese medicine, after hatching end, abandon culture fluid and add H2O2Processing 24 hours, cell is divided into normal group, H2O2(400 μm ol/mL) group, STL (0.1g/L) group, STL (0.1g/L)+H2O2(400 μm ol/mL) group, sirt1 inhibitor group, STL (0.1g/L)+H2O2(400 μm ol/mL)+inhibitor group.After acting on 36 hours, by cell with after 4 DEG C of PBS 2 times, scrape in the centrifuge tube that cell puts into 1.5mL with cell scraper after adding lysate, on ice cracking 30 minutes, used vortex oscillator to shake 30 seconds every 5 minutes.4 DEG C of 1000rpm are centrifuged 10 minutes, collect supernatant.Operate according to GSH test kit reagent preparation, detect by microplate reader.
6. the protein expression of sirt1, p21 in Western blot detection BMECs: test and after each group of cell cultivates termination, quantitative protein sample is carried out after 95 DEG C of degeneration 10min respectively electrophoresis and transferring film, then one anti-hatching 4 DEG C of overnight with two anti-incubated at room 1h, last ECL substrate chemiluminescence develops the color.
5) index determining
Cell proliferation vigor is detected according to mtt assay, DAPI staining detection apoptosis situation, beta galactosidase staining detection cell ageing situation, DCFH-DA probe loads detection cytoactive oxygen (ROS), SOD Activity determination, GSH Activity determination, the protein expression of sirt1, P21 in Western blot detection BMECs.
6) statistical procedures
Experimental data uses Sigma software analysis, Western blot data acquisition Image J software analysis, and data, with ± s histogram graph representation, use one factor analysis of variance, have statistical significance with P < 0.05 for difference between group.
Experimental result
Wherein, Fig. 1 is variable concentrations H2O2Impact on BMECs proliferation activity, variable concentrations H2O2(50-800 μm ol/L) processes after BMECs 24h, cell proliferation vigor increase with concentration for the treatment of and decline (**P ＜ 0.01), result shows: H2O2Can substantially suppress BMECs proliferation activity, 503nhibiting concentration (IC50) is 400 μm ol/L.
Fig. 2 is the variable concentrations STL impact on BEMCs proliferation activity, and variable concentrations STL (0.0125g/L-0.4g/L) processes after cell 12h, cell proliferation vigor along with concentration for the treatment of increase and rise (##P<0.01).Result shows: STL can be obviously promoted cell viability.
Fig. 3 is that the present invention is to H2O2The impact of the BMECs proliferation activity of induction, compares with normal group；H2O2(400 μm ol/L) group cell viability be decreased obviously (△△P<0.01)；With H2O2(400 μm ol/L) group is compared, variable concentrations STL (0.05g/L-0.2g/L)+H2O2(400 μm ol/L) group cell viability substantially increase (▲▲P ＜ 0.01).Result shows: STL can significantly inhibit H2O2The BMECs vigor of induction declines.
Fig. 4 is that the present invention is to H2O2The impact of the BMECs apoptosis situation of induction, as shown in Figure 4, the H that fluorescence microscopy Microscopic observation finds2O2(400 μm ol/L) processes 24h to stimulate after BMEC cell, karyopyknosis in the visual field, and dyeing is deepened, and apoptotic body occurs, or nuclear chromatin is crescent to be gathered in nuclear membrane, the corps ronds that notably karyorrhexis one-tenth differs in size.STL pretreated group cellular morphology substantially tends to normal and has dose dependent, rarely seen a small amount of core concentrating cells in high dose.Result shows: H2O2Apoptosis can be obviously promoted, and the present invention can significantly inhibit H2O2The BMECs apoptosis of induction.
Fig. 5 is that the present invention is to H2O2The impact of the old and feeble situation of the BMECs of induction, as shown in Figure 5, compares with normal group, H2O2(400 μm ol/L) processes 24h to stimulate in BMEC model group, and the activity of beta galactosidase is notable to be raised, and the visual field has most cells deeply to be dyed blueness, shows that model is successfully established.With H2O2(400 μm ol/L) group compares, and the activity of beta galactosidase gradually weakens along with the increase of STL dosage, and cellular colours, close to normal, be dyed to glaucous cell and significantly reduce, and in STL high dose pretreated group, cellular morphology tends to normal substantially.Result shows: H2O2Cell ageing can be obviously promoted, and the present invention can significantly inhibit H2O2The BMECs of induction is old and feeble.
Fig. 6 and Fig. 7 is that the present invention is to H2O2The ROS activity influence of the BMECs of induction, from Fig. 6 and Fig. 7, compares with normal group, H2O2(400 μm ol/L) group intracellular ROS level significantly raise (**P<0.01).With H2O2(400 μm ol/L) group is compared, STL (0.1g/L)+H2O2(400 μm ol/L) group intracellular ROS level significantly reduce (##P<0.01).With STL (0.1g/L)+H2O2(400 μm ol/L) group compares, add sirt1 inhibitor group intracellular ROS substantially increase (▲▲P ＜ 0.01).Result shows: the present invention can significantly inhibit H2O2The intracellular ROS of induction generates and oxidativestress damage.
Fig. 8 is that the present invention is to H2O2The SOD activity influence of the BMECs of induction, as shown in Figure 8, compares with normal group, H2O2(400 μm ol/L) organize intracellular SOD level be remarkably decreased (**P<0.01).With H2O2(400 μm ol/L) group is compared, STL (0.1g/L)+H2O2(400 μm ol/L) organize intracellular SOD level significantly raise (##P<0.01).With STL (0.1g/L)+H2O2(400 μm ol/L) group compares, add sirt1 inhibitor group intracellular SOD substantially reduce (▲▲P ＜ 0.01).Result shows: the present invention can dramatically increase H2O2The intracellular SOD of induction generates and inhibited oxidation stress damage, protects brain microvessel endothelial cells in vitro.
Fig. 9 is that the present invention is to H2O2The GSH level impact of the BMECs of induction, as shown in Figure 9, compares with normal group, H2O2(400 μm ol/L) organize intracellular GSH level be remarkably decreased (**P<0.01).With H2O2(400 μm ol/L) group is compared, STL (0.1g/L)+H2O2(400 μm ol/L) organize intracellular GSH level significantly raise (##P<0.01).With STL (0.1g/L)+H2O2(400 μm ol/L) group compares, add sirt1 inhibitor group intracellular GSH substantially reduce (▲▲P ＜ 0.01).Result shows: the present invention can dramatically increase H2O2The intracellular GSH of induction generates and inhibited oxidation stress damage, protects brain microvessel endothelial cells in vitro.
Figure 10 and Figure 11 is that the present invention is to H2O2The impact of the sirt1 protein expression level of the BMECs of induction, from Figure 10 and Figure 11, compares with normal group, H2O2The sirt1 protein expression that (400 μm ol/L) is organized substantially reduce (**P < 0.01), STL (0.1g/L) group sirt1 protein expression significantly raised (△P<0.05)；With H2O2(400 μm ol/L) group compares, STL (0.1g/L)+H2O2Sirt1 protein expression that (400 μm ol/L) is organized significantly raised (##P<0.01)；Compare with STL (0.1g/L) group, the sirt1 protein expression of STL (0.1g/L)+inhibitor group substantially reduce (▽▽P<0.01)；With STL (0.1g/L)+H2O2(400 μm ol/L) group compares, STL (0.1g/L)+H2O2The sirt1 protein expression of (400 μm ol/L)+inhibitor group substantially reduce (▲▲P<0.01).Result shows: energy inhibited oxidation stress damage of the present invention, protects brain microvessel endothelial cells in vitro, and this effect is relevant with sirt1 signal path.
Figure 12 and Figure 13 is that the present invention is to H2O2The impact of the p21 protein expression level of the BMECs of induction, from Figure 12 and Figure 13, compares with normal group, H2O2P21 protein expression that (400 μm ol/L) is organized significantly raised (**P < 0.01), STL (0.1g/L) group p21 protein expression substantially reduce (△P<0.05)；With H2O2(400 μm ol/L) group compares, STL (0.1g/L)+H2O2The p21 protein expression that (400 μm ol/L) is organized substantially reduce (##P<0.01)；Compare with STL (0.1g/L) group, the p21 protein expression of STL (0.1g/L)+inhibitor group significantly raised (▽▽P<0.01)；With STL (0.1g/L)+H2O2(400 μm ol/L) group compares, STL (0.1g/L)+H2O2The p21 protein expression of (400 μm ol/L)+inhibitor group significantly raised (▲▲P<0.01).Result shows: energy inhibited oxidation stress damage of the present invention, protects brain microvessel endothelial cells in vitro, and this effect is relevant with p21 signal path.
Figure 14 and Figure 15 is that the present invention is to H2O2The impact of the PCG-1 α protein expression level of the BMECs of induction, from Figure 14 and Figure 15, compares with normal group, H2O2The PCG1-α protein expression that (400 μm ol/L) is organized substantially reduce (**P < 0.01), STL (0.1g/L) group PCG-1 α protein expression significantly raised (△P<0.05)；With H2O2(400 μm ol/L) group compares, STL (0.1g/L)+H2O2PCG-1 α protein expression that (400 μm ol/L) is organized significantly raised (##P<0.01)；Compare with STL (0.1g/L) group, the PCG-1 α protein expression of STL (0.1g/L)+inhibitor group substantially reduce (▽▽P<0.01)；With STL (0.1g/L)+H2O2(400 μm ol/L) group compares, STL (0.1g/L)+H2O2The PCG-1 α protein expression of (400 μm ol/L)+inhibitor group substantially reduce (▲▲P<0.01).Result shows: energy inhibited oxidation stress damage of the present invention, protects brain microvessel endothelial cells in vitro, and this effect is relevant with PGC-1 alpha signal path.
Experiment conclusion
By present invention discover that the cell proliferation vigor of the brain microvessel endothelial cells in vitro strengthening hydrogen peroxide induction, suppress cell ageing, apoptosis；Reduce ROS activity, improve SOD, GSH activity；Improve sirt1, PGC-1 α protein expression, reduce p21 protein expression.The apoptosis of the easy trigger cell of oxidative stress, old and feeble equivalent damage.PCG-1 α is the emerging transcription regulaton factor played a crucial role in anti-oxidation stress system, when oxidative stress, PGC-1 alpha active raises scalable cell effect, it can induce antioxidase such as glutathione peroxidase (GSH-PX), the expression of superoxide dismutase (SOD), improves tissue oxidation resistance.Prevent proteasomal degradation PGC-1 α after sirt1 deacetylation PGC-1 α and the gene expression of the antioxidase such as sustained activation GSH, SOD, and then reduce the generation of free radical, reach antioxidative purpose.Therefore the present invention can protect cerebrovascular by activating sirt1 signal path regulation and control PGC-1 α anti-oxidation stress, prevent and treat ischemic cerebrovascular.It addition, the DNA damage that oxidative stress can cause can raise the activity of aging gene p21, cause aging.Therefore the present invention can be by lowering aging and then the preventing and treating ischemic encephalopathy of p21 expression inhibiting vascular endothelial cell.
Clinical trial embodiment
Based on above-mentioned experimental result, Chinese medicine composition the most of the present invention fermentation liquid medicine applying brain microvessel endothelial cells in vitro oxidativestress damage effect is obvious；Brain microvessel endothelial cells in vitro apoptosis and the aging of hydrogen peroxide induction can be significantly inhibited.In the case of informed consent and on the basis of human treatment, clinical practice tests the therapeutic effect of the present invention in chronic cerebral ischemia patient.
Physical data
Choose SanXia University's hospital of traditional Chinese hospital's outpatient service and Acute Ischemic Stroke Patients 80 example being in hospital, wherein male 39 example, women 41 example, age 30～80 years old during in January, 2013 in January, 2016；The course of disease is 3d-60d, is randomly divided into treatment group 40 example, matched group 40 example.The neurological functional deficit scale treating front two groups of patients is compared, two groups of clinical data no significant difference (P > 0.05).
Diagnostic criteria
Cerebral thrombosis diagnostic criteria that 1. Western medicine diagnose standard is revised according to nineteen ninety-five whole nation cerebrovascular academic conference (the 4th national cerebrovascular meeting. the classification of cerebrovascular disease and diagnostic criteria. China's neurosurgery magazine, 1997；13 (1): 2).
2. Chinese medical discrimination belongs to apoplex involving the channels and collaterals, wind heat blood stasis, numbness resistance passages through which vital energy circulates patient.Disease sees hemiplegia, crooked mouth and tongue, and speech is not smoothgoing puckery or in silence, and hemianesthesia is dizzy, dark tongue quality or dark red or have ecchymosis, yellow and thin fur or Huang, stringy pulse or stringy and thready pulse, and knows unconsciousness without god.And according to new Chinese medicine clinical observation guideline (Ministry of Health of the People's Republic of China formulates. new Chinese medicine guideline of clinical investigations. first volume of .1993:32) determine observation case standard and observation index.
Therapeutic Method
Treatment group Chinese medicine composition of the present invention for oral use fermentation medicinal liquid, each 60ml, it is administered orally three times a day, 30d is a course for the treatment of.Matched group takes Xuesaitong dispersible tablet, each 2 (100mg), three times a day.The medicine of other cerebrovascular is disabled during observation.
Curative effect determinate standard
Use apoplexy scoring system, evaluate mind, language, motor function recovery degree.Indices is divided into 5 grades (0～4), and total score is 28 points, the most artificial 0 point；Before treatment, starting point is divided and minimum is not less than 18 points；Efficacy evaluation method is integration after integration-treatment before treatment) integration × 100% after/treatment；It is almost recovered >=85%；Effective >=50%；Effectively >=20%；Invalid≤20%.
Therapeutic outcome
Treatment group and matched group clinical cure are respectively as follows: 15 examples (25%), 7 examples (17.5%)；Effective respectively 33 examples (82.5%) and 17 examples (42.5%)；Effectively it is respectively 38 examples (95%), 30 examples (75%)；Invalid 2 examples (5%), 10 examples (25%).Two groups of obvious effective rate comparing differences have significance,statistical meaning (P < 0.01), show that treatment group curative effect is better than matched group.
In the change herb fermenting of the present invention medicinal liquid waited of curing the desease to patient's hemianesthesia, the improvement waited of curing the desease in headache and dizzy, and body of the tongue, tongue fur etc. is more apparent.
Table 1 is the change of TCM syndrome before and after the treatment for the treatment of group.
TCM syndrome Before treatment/example After treatment/example Disappearance rate/%
Hemiplegia, numbness 25 11 56
Stiff tongue and retardation in speech 24 14 41.7
Headache, dizzy, tinnitus 32 12 62.5
Red tongue, yellow fur 33 16 51.5
Table 1
Before the change treatment of comprehensive function, the comprehensive function score value for the treatment of group and matched group is respectively 3.44 ± 0.61 and 3.57 ± 0.61, and two groups are compared and there was no significant difference (P > 0.05)；Being respectively 1.49 ± 1.41 and 2.85 ± 1.57 after treatment, two groups are compared and have significant difference (P < 0.01), show that treatment group is better than matched group.
Typical case
Case 1
Huang, man, 58 years old, peasant, first visit on April 4 in 2013.Previously having more than 10 years of history of hypertension, interruption is taken medicine, and before telling January, morning plays numb limbs and tense tendons on the right side of unexpected sensation, does not gives attention, increases the weight of in Progressive symmetric erythrokeratodermia to accompany dizziness headache, show in certain county hospital brain CT examination: the multiple infarction in left brain basal ganglia region after 10d.Because being reluctant that hospitalization, outpatient service then are seen a doctor.See quarter: soft-fat type, and god is clear, and aphasia is had a dizzy spell, flushing, irritated, right side limb adynamia, movable difficulty, diet can, big dry stool, urine is normal, and the tongue dim red Sublingual stasis of blood is stagnant, thick, yellow and greasy fur, stringy and rolling pulse.Give Chinese medicine composition of the present invention for oral use fermentation liquid medicine applying, each 60ml, be administered orally three times a day, treat 30d.On May 5th, 2013 examines again, sees that patient includes that the major part symptoms such as numb limbs and tense tendons, language problem, dizziness headache, coordination obstacle significantly improve, and can keep good body steadiness and balance during action.
Case 2
Xiong, man, 77 years old, in first visit on October 12 in 2014.Main suit: be slow in action, dull mind 3 months.After patient suffered from cerebral infarction before 2 years, right side limb activity is unfavorable, and hypomnesis and thinking bradykinesia gradually increase the weight of, there is not remembering clearly the age of oneself, meet kith and kin and can not think address, go out to get lost, computing capability is decreased obviously, and used article can not find, and can't take care of oneself, examine as " vascular dementia ", through repeatedly diagnosis and treatment, DeGrain, seek medical advice in inventor.See quarter: on the right side of patient, limb activity is unfavorable, and bradykinesia be can't take care of oneself, and has a dull expression on one's face, crooked mouth and tongue, memory, computing capability lose, receive can, difference of sleeping, light red tongue, yellow and greasy fur, stringy and rolling pulse.Give Chinese medicine composition of the present invention for oral use fermentation liquid medicine applying, each 60ml, be administered orally three times a day, treat 20d.On November 2nd, 2014 examines again, sees that limbs of patient mobility is obviously improved, and memory ability has improvement, can recognize household and relative.Patient is advised to continue oral Chinese medicine composition of the present invention fermentation medicinal liquid March.On March 10th, 2015 this patient of call-on back by phone, patient's private prosecution limb activity ability returns to one's perfect health, and can remember and doctor's diagnosis and treatment process, and can remember the relevant informations such as the name of oneself, age, and self-care ability is obviously enhanced.

Claims (10)

1. a Chinese medicine composition, it is characterised in that include following raw material by weight:
Radix Puerariae 160-480 part, Radix Salviae Miltiorrhizae 80-320 part, Radix Paeoniae Alba 120-400 part, Radix Astragali 120-400 part, Rhizoma Curcumae Longae 40-240 part, Rhizoma Atractylodis Macrocephalae 60-280 part, Semen Sinapis Albae 40-240 part, Fructus Crataegi 60-280 part, Radix Bupleuri 60-280 part, Flos Chrysanthemi 60-280 part, Rhizoma Gastrodiae 40-240 part, Rhizoma Panacis Japonici 60-280 part, Rhizoma Cyperi 60-280 part, Herba Salviae Chinensis 40-240 part.
Chinese medicine composition the most according to claim 1, it is characterised in that: Radix Puerariae 320 parts, Radix Salviae Miltiorrhizae 160 parts, the Radix Paeoniae Alba 240 parts, the Radix Astragali 240 parts, 80 parts of Rhizoma Curcumae Longae, the Rhizoma Atractylodis Macrocephalae 120 parts, Semen Sinapis Albae 80 parts, Fructus Crataegi 120 parts, Radix Bupleuri 120 parts, Flos Chrysanthemi 120 parts, 80 parts of Rhizoma Gastrodiae, Rhizoma Panacis Japonici 120 parts, Rhizoma Cyperi 120 parts, Herba Salviae Chinensis 80 parts.
3. the preparation method of the Chinese medicine composition described in claim 1 or 2, it is characterized in that: raw material of Chinese medicine will be weighed by proportioning, add the water of raw material gross weight 8-10 times, first intense fire is heated to seething with excitement slow fire boiling 30-60min again, decoct to the 4-5 times of water yield, remove slag and be filtrated to get the decocting for Chinese herbal medicine liquid of this Chinese medicine composition.
Preparation method the most according to claim 3, it is characterised in that: the raw material of Chinese medicine after adding water first soaks 20-60min, then carries out heating and decocts.
5. the fermentation medicinal liquid of a Chinese medicine composition, it is characterised in that by weight: containing yeast 10-50 part, acetobacter 10-50 part, lactobacillus 10-50 part, remaining the decocting for Chinese herbal medicine liquid prepared for Chinese medicine composition in every 10000 parts of fermentation medicinal liquids.
The fermentation medicinal liquid of Chinese medicine composition the most according to claim 5, it is characterized in that: by weight: containing 10 parts of yeast, acetobacter 10 parts, lactobacillus 10 parts, remaining the decocting for Chinese herbal medicine liquid prepared for Chinese medicine composition in every 10000 parts of fermentation medicinal liquids.
7. the method preparing the medicinal liquid that ferments described in claim 5 or 6, it is characterised in that concretely comprise the following steps: after taking yeast, acetobacter and lactobacillus by proportioning, add decocting for Chinese herbal medicine liquid, 22-37 DEG C of bottom fermentation 10-20 days, filtering, sterilization i.e. can obtain the medicinal liquid finished product that ferments.
8. the fermentation medicinal liquid of the Chinese medicine composition described in claim 1-4 or the Chinese medicine composition described in claim 5-7 application in terms of preparation treatment ischemic encephalopathy medicine.
9. the fermentation medicinal liquid of the Chinese medicine composition described in claim 1-4 or the Chinese medicine composition described in claim 5-7 application in terms of apoptosis of vascular endothelial cell medicine caused by preparation treatment oxidative stress.
10. the fermentation medicinal liquid of the Chinese medicine composition described in claim 1-4 or the Chinese medicine composition described in claim 5-7 application in terms of the medicines such as preparation treatment vascular dementia, headache, dizziness, tinnitus.
CN201610302578.1A 2016-05-09 2016-05-09 A kind of Chinese medicine composition, fermentation medical fluid of its preparation and preparation method and application Expired - Fee Related CN105833184B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610302578.1A CN105833184B (en) 2016-05-09 2016-05-09 A kind of Chinese medicine composition, fermentation medical fluid of its preparation and preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610302578.1A CN105833184B (en) 2016-05-09 2016-05-09 A kind of Chinese medicine composition, fermentation medical fluid of its preparation and preparation method and application

Publications (2)

Publication Number Publication Date
CN105833184A true CN105833184A (en) 2016-08-10
CN105833184B CN105833184B (en) 2019-07-26

Family

ID=56591606

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610302578.1A Expired - Fee Related CN105833184B (en) 2016-05-09 2016-05-09 A kind of Chinese medicine composition, fermentation medical fluid of its preparation and preparation method and application

Country Status (1)

Country Link
CN (1) CN105833184B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106667905A (en) * 2017-03-20 2017-05-17 河南省长义农业科技有限公司 Method for producing complete plant enzyme/traditional Chinese medicine oral liquid
CN107823458A (en) * 2017-11-29 2018-03-23 徐小毛 It is a kind of to be used to treat apoplexy and the Chinese medicine of apoplexy complication and preparation method thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1087275A (en) * 1992-11-28 1994-06-01 中国人民解放军第371医院 Treatment ischemic brain, cardiovascular preparation Shumaining
CN1437959A (en) * 2002-02-10 2003-08-27 杨志东 Chinese prepartory for treating cardiovascular and cerebrovascular disease and preparation method
CN1872329A (en) * 2005-06-03 2006-12-06 天津天士力制药股份有限公司 Application of medication composition of containing giant gen-seng in preparing medicine for treating insufficiency of blood supply for brain
CN101314002A (en) * 2008-07-21 2008-12-03 秦周顺 Medicament for treating blood supply insufficiency of brain
CN101780223A (en) * 2010-04-09 2010-07-21 任添华 Traditional Chinese medicine with integral coordination function for treating ischemic cerebrovascular disease
CN102727819A (en) * 2012-07-05 2012-10-17 陈光明 Baokangling multi-element probiotics oral liquid for treating digestive system disease and preparation method thereof
CN103736037A (en) * 2014-01-28 2014-04-23 张怀胜 Medicine for treating chronic fatigue syndrome and preparation method thereof
CN104013831A (en) * 2014-06-05 2014-09-03 黄艳梅 Medicament for treating insufficient blood supply

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1087275A (en) * 1992-11-28 1994-06-01 中国人民解放军第371医院 Treatment ischemic brain, cardiovascular preparation Shumaining
CN1437959A (en) * 2002-02-10 2003-08-27 杨志东 Chinese prepartory for treating cardiovascular and cerebrovascular disease and preparation method
CN1872329A (en) * 2005-06-03 2006-12-06 天津天士力制药股份有限公司 Application of medication composition of containing giant gen-seng in preparing medicine for treating insufficiency of blood supply for brain
CN101314002A (en) * 2008-07-21 2008-12-03 秦周顺 Medicament for treating blood supply insufficiency of brain
CN101780223A (en) * 2010-04-09 2010-07-21 任添华 Traditional Chinese medicine with integral coordination function for treating ischemic cerebrovascular disease
CN102727819A (en) * 2012-07-05 2012-10-17 陈光明 Baokangling multi-element probiotics oral liquid for treating digestive system disease and preparation method thereof
CN103736037A (en) * 2014-01-28 2014-04-23 张怀胜 Medicine for treating chronic fatigue syndrome and preparation method thereof
CN104013831A (en) * 2014-06-05 2014-09-03 黄艳梅 Medicament for treating insufficient blood supply

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106667905A (en) * 2017-03-20 2017-05-17 河南省长义农业科技有限公司 Method for producing complete plant enzyme/traditional Chinese medicine oral liquid
CN107823458A (en) * 2017-11-29 2018-03-23 徐小毛 It is a kind of to be used to treat apoplexy and the Chinese medicine of apoplexy complication and preparation method thereof

Also Published As

Publication number Publication date
CN105833184B (en) 2019-07-26

Similar Documents

Publication Publication Date Title
CN102078520A (en) Chinese medicinal preparation for treating nervous headache and preparation method thereof
CN104147345B (en) A kind of Chinese medicine composition for treating cardiovascular autonomic neuropathy
CN104906465A (en) Traditional Chinese medicine blood-stasis dispersing composition for treating woman chronic pelvic inflammation and preparation method thereof
CN105833184A (en) Traditional Chinese medicine composition, fermented medicine liquor prepared from traditional Chinese medicine composition, preparation method and application
CN102188638A (en) Medicament for treating liver cancer
CN115252691B (en) Traditional Chinese medicine composition for treating qi stagnation and blood stasis type coronary heart disease angina
CN103520552A (en) Traditional Chinese medicine composition for treating acute conjunctivitis and preparation method thereof
CN102614462B (en) Traditional Chinese medicine composition for curing coronary disease and preparation method thereof
CN101757408A (en) Medicament for treating lupus erythematosus and preparation method thereof
CN102049010B (en) Medicament for preventing and treating ischemic cerebrovascular diseases
CN103751679A (en) Preparation method of traditional Chinese medicine for treating liver/kidney-yin-deficiency-type hyperlipemia
CN103316214B (en) Chinese medicine composition for treating viral myocarditis and preparation method thereof
CN101732425B (en) Externally-applied medicine composite for psoriasis
CN104906394A (en) Traditional Chinese medicine for treating liver and kidney yin deficiency and qi and blood deficiency type hypertension
CN104667183A (en) Medicine preparation for treating damp-heat evil stagnation type pyogenic osteomyelitis and preparation method of medicine preparation
CN104740579B (en) Premenstrual peace piece and its preparation technology
CN108524740A (en) A kind of Chinese medicinal formulae for treating rheumatoid arthritis
CN103330775A (en) Traditional Chinese medicine fuming composition used for treatment of varicose vein of lower limb
CN103202938A (en) Traditional Chinese medicine decoction for treating enteritis
CN103285328A (en) Traditional Chinese medicine composition capsule for treating coronary heart diseases and preparation method thereof
CN116211987B (en) Traditional Chinese medicine composition for treating refractory endocrine drug-resistant breast cancer, traditional Chinese medicine preparation and application thereof
CN106727752A (en) Treat pharmaceutical composition of synovitis and preparation method thereof
CN107213293B (en) Traditional Chinese medicine composition for treating chronic cerebral circulation insufficiency and preparation method thereof
CN105770354A (en) Medicament for treating chronic nephritis and preparation method thereof
CN104857371A (en) Medicine for treating colon cancer and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20210511

Address after: Room 703-1 and 703-2, 7 / F, Qinzhou hi tech Industry Service Center (incubation complex building), 9 Longxiang Road, Qinzhou City, Guangxi Zhuang Autonomous Region, 535000

Patentee after: Guangxi chuse Biotechnology Co.,Ltd.

Address before: No.716, 7th floor, building 4, No.99 Guangfu Road, Wuhou District, Chengdu, Sichuan 610000

Patentee before: Chengdu yishenrui Technology Co.,Ltd.

Effective date of registration: 20210511

Address after: No.716, 7th floor, building 4, No.99 Guangfu Road, Wuhou District, Chengdu, Sichuan 610000

Patentee after: Chengdu yishenrui Technology Co.,Ltd.

Address before: 443002 No. 8, University Road, Yichang, Hubei

Patentee before: CHINA THREE GORGES University

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190726